| Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci A Franke, DPB McGovern, JC Barrett, K Wang, GL Radford-Smith, ... Nature genetics 42 (12), 1118-1125, 2010 | 3148 | 2010 |
| Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47 CA Anderson, G Boucher, CW Lees, A Franke, M D'Amato, KD Taylor, ... Nature genetics 43 (3), 246-252, 2011 | 1718 | 2011 |
| Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility International Multiple Sclerosis Genetics Consortium*†, ANZgene, ... Science 365 (6460), eaav7188, 2019 | 922 | 2019 |
| Comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors CAM Stedman, ML Barclay Alimentary pharmacology & therapeutics 14 (8), 963-978, 2000 | 519 | 2000 |
| Aminoglycosides--50 years on. EJ Begg, ML Barclay British journal of clinical pharmacology 39 (6), 597, 1995 | 430 | 1995 |
| High incidence of Crohn's disease in Canterbury, New Zealand: results of an epidemiologic study RB Gearry, A Richardson, CMA Frampton, JA Collett, MJ Burt, ... Inflammatory bowel diseases 12 (10), 936-943, 2006 | 346 | 2006 |
| High-density mapping of the MHC identifies a shared role for HLA-DRB1* 01: 03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis P Goyette, G Boucher, D Mallon, E Ellinghaus, L Jostins, H Huang, ... Nature genetics 47 (2), 172-179, 2015 | 338 | 2015 |
| Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment LK Stamp, JL O'Donnell, M Zhang, J James, C Frampton, ML Barclay, ... Arthritis & Rheumatism 63 (2), 412-421, 2011 | 312 | 2011 |
| Population‐based cases control study of inflammatory bowel disease risk factors RB Gearry, AK Richardson, CM Frampton, AJ Dodgshun, ML Barclay Journal of gastroenterology and hepatology 25 (2), 325-333, 2010 | 298 | 2010 |
| consensus statements on therapeutic drug monitoring of anti‐tumour necrosis factor therapy in inflammatory bowel diseases N Mitrev, N Vande Casteele, CH Seow, JM Andrews, SJ Connor, ... Alimentary pharmacology & therapeutics 46 (11-12), 1037-1053, 2017 | 294* | 2017 |
| Azathioprine and 6‐mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease RB Gearry, ML Barclay Journal of gastroenterology and hepatology 20 (8), 1149-1157, 2005 | 288 | 2005 |
| Perianal disease predicts changes in Crohn's disease phenotype—results of a population-based study of inflammatory bowel disease phenotype KM Tarrant, ML Barclay, CMA Frampton, RB Gearry Official journal of the American College of Gastroenterology| ACG 103 (12 …, 2008 | 273 | 2008 |
| The spectrum of perianal Crohn’s disease in a population-based cohort TW Eglinton, ML Barclay, RB Gearry, FA Frizelle Diseases of the colon & rectum 55 (7), 773-777, 2012 | 269 | 2012 |
| Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis JM Dalrymple, LK Stamp, JL O'Donnell, PT Chapman, M Zhang, ... Arthritis & Rheumatism: Official Journal of the American College of …, 2008 | 247 | 2008 |
| A suggested approach to once‐daily aminoglycoside dosing. EJ Begg, ML Barclay, SB Duffull British journal of clinical pharmacology 39 (6), 605-609, 1995 | 232 | 1995 |
| Population‐based epidemiology study of autoimmune hepatitis: a disease of older women? JH Ngu, K Bechly, BA Chapman, MJ Burt, ML Barclay, RB Gearry, ... Journal of gastroenterology and hepatology 25 (10), 1681-1686, 2010 | 226 | 2010 |
| Reasons for failure to diagnose colorectal carcinoma at colonoscopy M Leaper, MJ Johnston, M Barclay, BR Dobbs, FA Frizelle Endoscopy 36 (06), 499-503, 2004 | 198 | 2004 |
| Submental surface electromyographic measurement and pharyngeal pressures during normal and effortful swallowing ML Huckabee, SG Butler, M Barclay, S Jit Archives of physical medicine and rehabilitation 86 (11), 2144-2149, 2005 | 179 | 2005 |
| Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease RB Gearry, ML Barclay, MJ Burt, JA Collett, BA Chapman Pharmacoepidemiology and drug safety 13 (8), 563-567, 2004 | 176 | 2004 |
| Systematic review with meta‐analysis: SARS‐CoV‐2 stool testing and the potential for faecal‐oral transmission AS van Doorn, B Meijer, CMA Frampton, ML Barclay, NKH de Boer Alimentary pharmacology & therapeutics 52 (8), 1276-1288, 2020 | 174 | 2020 |
Evan BeggProfessor of Medicine在 otago.ac.nz 的电子邮件经过验证
